REACT assesses clazosentan for the prevention of clinical deterioration due to vasospasm-related delayed cerebral ischemia following subarachnoid hemorrhage Japanese registration program with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback